URGN Q1 2017 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$918M

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19,000

Gross Profit

$1,0005.3% margin

Operating Income

-$4M-18621.1% margin

Net Income

-$3M-17984.2% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

-99.9%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$297,000

Balance Sheet

Total Assets

$0

Total Liabilities

$0

Stockholders' Equity

$20M

Cash & Equivalents

-$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19,000	$0	—
Gross Profit	$1,000	$0	—
Operating Income	-$4M	-$4M	+1.7%
Net Income	-$3M	-$4M	+17.9%